Search research articles
Contact Us
Filters
Showing results (111-120 of 162) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
Kenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Clinical Colorectal Cancer
|
November 22, 2011
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial
Mace L Rothenberg, P Y Liu, Patricia S Braly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1991
Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials
J A O'Shaughnessy, R E Wittes, G Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
Mace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1996
New anticancer agents
G R Weiss, H A Burris 3rd, J R Eckardt, et al.
Clinical Pharmacology and Therapeutics
|
October 7, 2011
Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects
L B Katz, J J Gambale, P L Rothenberg, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 162) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
Kenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Clinical Colorectal Cancer
|
November 22, 2011
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial
Mace L Rothenberg, P Y Liu, Patricia S Braly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1991
Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials
J A O'Shaughnessy, R E Wittes, G Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
Mace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1996
New anticancer agents
G R Weiss, H A Burris 3rd, J R Eckardt, et al.
Clinical Pharmacology and Therapeutics
|
October 7, 2011
Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects
L B Katz, J J Gambale, P L Rothenberg, et al.
Page
of 17